Monday, June 12, 2017

BRIEF-Foamix announces dosing of first patient in phase 3 rosacea clinical trials

* Foamix announces dosing of first patient in phase 3 rosacea clinical trials for FMX103 minocycline foam 1.5%

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)